Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.04.503
Annals of Surgical Oncology 12:995-1004 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pipas, J. M.
Right arrow Articles by Colacchio, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pipas, J. M.
Right arrow Articles by Colacchio, T. A.

Original Article

Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma

J. Marc Pipas, MD, Richard J. Barth, Jr., MD, Bassem Zaki, MD, Michael J. Tsapakos, MD, Arief A. Suriawinata, MD, Michael A. Bettmann, MD, Justin M. Cates, MD, PhD, Gregory H. Ripple, MD, John E. Sutton, MD, Stuart R. Gordon, MD, Carol E. McDonnell, CCRP, Raymond P. Perez, MD, Nancy Redfield, ARNP, Louise P. Meyer, ARNP, John F. Marshall, MD, Bernard F. Cole, PhD and Thomas A. Colacchio, MD

Gastrointestinal Oncology Program, Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, New Hampshire 03756

Correspondence: Address correspondence and reprint requests to: J. Marc Pipas, MD; E-mail: j.marc.pipas{at}hitchcock.org.

Background: Pancreatic cancer remains highly lethal. Previous attempts with neoadjuvant therapy in this disease have been inconclusive, but a potential for benefit exists. We conducted a phase II trial of dose-intense docetaxel and gemcitabine followed by twice-weekly gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.

Methods: Patients with stage I to III disease were eligible. Docetaxel 65 mg/m2 intravenously over 1 hour and gemcitabine 4000 mg/m2 given intravenously over 30 minutes were given on days 1, 15, and 29. On day 43, radiotherapy was begun at 50.4 Gy with gemcitabine 50 mg/m2 intravenously over 30 minutes twice weekly for 12 doses. After treatment, patients were considered for resection.

Results: Twenty-four assessable patients were recruited onto the trial. All but one patient completed a full 12 weeks of therapy. Grade 3 and 4 hematological and nonhematological toxicities were common but manageable, and neutropenic fever did not occur. No patient had local tumor progression. Twelve patients (50%) responded by Response Evaluation Criteria in Solid Tumors Group (RECIST) criteria, including one radiographic complete response. Seventeen patients underwent resection after therapy. Margin-negative resections were performed in 13 patients, including 9 patients whose disease was borderline or unresectable before treatment. A treatment effect was seen in all resection specimens. There have been no local recurrences of tumor, and several patients remain alive without evidence of disease.

Conclusions: Docetaxel/gemcitabine followed by gemcitabine/radiotherapy is active in the treatment of pancreatic adenocarcinoma, with manageable toxicity. Tumor downstaging occurs in some patients to allow complete resection. Further investigation of this regimen is warranted.

Key Words: Pancreatic adenocarcinoma • Radiotherapy • Gemcitabine • Docetaxel • Neoadjuvant




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
U. Distler, J. Souady, M. Hulsewig, I. Drmic-Hofman, J. Haier, A. Denz, R. Grutzmann, C. Pilarsky, N. Senninger, K. Dreisewerd, et al.
Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
Mol. Cancer Ther., August 1, 2008; 7(8): 2464 - 2475.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.